EGFR-targeted therapy for lung cancer

Targeted therapy is chosen after testing identifies a relevant EGFR alteration. Unlike a treatment selected only by where a tumour began, it is matched to a feature in tumour cells. It may be used alone or alongside other approaches, depending on whether the cancer is localised, has spread, or has changed after earlier treatment.

The medicine, dose, schedule, and monitoring plan vary. Treatment may continue while it is helping and side effects remain manageable, with decisions adjusted by scans, symptoms, and laboratory checks.

Give your team a complete list of medicines, supplements, and allergies because interactions can affect treatment. Ask how and when to take each dose, what to do after vomiting or a missed dose, and whether food affects it. Keep planned appointments so the team can assess skin, bowel, liver, lung, and other possible effects. Do not change the dose without advice.

Report severe or persistent diarrhoea, reduced urination, inability to drink, painful mouth sores, a rapidly worsening rash, eye symptoms, yellowing of the skin, or unusual tiredness. New or worsening cough, breathlessness, or chest discomfort needs prompt medical advice because lung inflammation can require urgent treatment.

What EGFR result supports this medicine? What benefit are we aiming for? Which side effects should I record at home? Which medicines or foods should I avoid? How will scans and blood tests guide the next decision?